Current Situation
Adjuvantix has committed funding from its investors to undertake extensive comparative pre-clinical studies against other vaccine adjuvant systems. These studies are likely to take up to two years to complete. Adjuvantix anticipates that these will confirm the advantages of ADX40 and allow the company to raise further funding to undertake the development of lead vaccine candidates.